<DOC>
<DOCNO>EP-0641346</DOCNO> 
<TEXT>
<INVENTION-TITLE>
7'-AMINO-NAPHTHAZARIN ANTIBIOTIC DERIVATIVES
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K3135	A61K3135	C07D49320	C07D49300	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	C07D	C07D	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K31	C07D493	C07D493	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
New naphthazarin derivatives of formula (I) obtained by introducing in the 7' position of Purpuromycin or  gamma -Rubromycin an amino or a monosubstituted amino group. The compounds of the invention show antibiotic activity against Gram positive and Gram negative microorganisms, fungi and protozoa and are suitable for the treatment of vaginal infections. Compounds of formula (IV) and (V) are also claimed.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
LEPETIT SPA
</APPLICANT-NAME>
<APPLICANT-NAME>
GRUPPO LEPETIT S.P.A.
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
CIABATTI ROMEO
</INVENTOR-NAME>
<INVENTOR-NAME>
DALLANOCE CLELIA MARIANGIOLA L
</INVENTOR-NAME>
<INVENTOR-NAME>
TRANI ALDO
</INVENTOR-NAME>
<INVENTOR-NAME>
CIABATTI, ROMEO
</INVENTOR-NAME>
<INVENTOR-NAME>
DALLANOCE, CLELIA, MARIANGIOLA, LUISA
</INVENTOR-NAME>
<INVENTOR-NAME>
TRANI, ALDO
</INVENTOR-NAME>
</INVENTORS>
<DESCRIPTION>
The present invention concerns novel naphthazarin 
antibiotic derivatives having general formula I 
 
and the pharmaceutically acceptable addition salts 
thereof, wherein: 
R represents hydrogen or hydroxy; R1 represents hydrogen or an -alk-X group wherein 
alk represents a (C1-C4) alkylene and X represents hydrogen, hydroxy, cyano, 
trifluoromethyl, 
or a -NR2R3 group 
wherein R2 and R3 independently represent hydrogen, 
(C1-C4) alkyl or an amino-protecting group selected from 
(C1-C5)alkoxycarbonyl, (C2-C4)alkenyloxycarbonyl, 
cinnamyloxycarbonyl, benzyloxycarbonyl, p-nitrobenzyloxycarbonyl, 
3,4-dimethoxy-6-nitrobenzyloxycarbonyl, 
2,4-dichloro-benzyloxycarbonyl, 
5-benzylisoxazolyl-methoxycarbonyl, 9-anthranylmethoxycarbonyl,  
 
diphenylmethoxycarbonyl, 
isonicotinyloxycarbonyl and S-benzyloxycarbonyl. These novel naphthazarin antibiotic derivatives 
are characterized by having an amino or monosubstituted 
amino group linked to the 7' position of the molecule. Preferred compounds are those of formula I wherein 
R is hydrogen or hydroxy; R1 represents hydrogen or an -alk-X group wherein 
alk is a methylenic, ethylenic or propylenic 
moiety; X is hydrogen, hydroxy, cyano, trifluoromethyl or 
a -NR2R3 group wherein R2 and R3 independently 
represent hydrogen, methyl or butyloxycarbonyl. Most preferred compounds are those wherein R is 
hydroxy, alk is methylen and X is hydrogen. In the present description, the terms used above 
in defining the meanings of R and R1 are intended to 
have the meanings commonly assigned to them in the art. The following list exemplifies in particular some 
of them: 
(C1-C4) alkylene represents a bifunctional linear or 
branched hydrocarbon moiety containing 1, 2, 3 or 4 
carbon atoms such as: 
-CH2-, -CH2-CH2-, -CH(CH3)- -CH2-CH2-CH2-, -CH(CH3)-CH2-, -CH2-CH2-CH2-CH2-,  
 -CH(CH3)-CH2-CH2-, -C(CH3)2-CH2-; (C1-C4) alkyl represents a linear or branched 
hydrocarbon moiety containing 1, 2, 3 or 4 carbon atoms 
such as: 
-CH3, -CH2-CH3, -CH2-CH2-CH3, -CH-(CH3)2, -CH2-CH2-CH2-CH3, -CH(CH3)-CH2-CH3, -CH2-CH(CH3)-CH3, -C-(CH3)3; (C1-C4) alkoxy represents a linear or branched ether 
moiety containing 1, 2, 3 or 4 carbon atoms such as: 
-O-CH3, -O-CH2-CH3, -O-CH2-CH2-CH3, -O-CH-(CH3)2, -O-CH2-CH2-CH2-CH3, -O-CH(CH3)-CH2-CH3, -O-CH2-CH(CH3)-CH3, -O-C-(CH3)3; (C1-C5) alkoxycarbonyl and (C2-C4) alkenyloxycarbonyl 
represent a linear or branched hydrocarbon moiety from 1 
to 5 and from 2 to 4 carbon atoms, respectively, 
containing a carboxylic function, such as: 
-CO-O-CH3,
</DESCRIPTION>
<CLAIMS>
Naphthazarin antibiotic derivatives having general 
formula I 


 
and the pharmaceutically acceptable addition salts 

thereof, wherein: 

R represents hydrogen or hydroxy; 
R
1
 represents hydrogen or an -alk-X group wherein 

alk represents a (C
1
-C
4
) alkylene and 
X represents hydrogen, hydroxy, cyano, 
trifluoromethyl or a -NR
2
R
3
 group wherein R
2
 and R
3
 
independently represent hydrogen, (C
1
-C
4
) alkyl or an 
amino-protecting group selected from (C
1
-C
5
)alkoxycarbonyl, 
(C
2
-C
4
)alkenyloxycarbonyl, cinnamyloxycarbonyl, 
benzyloxycarbonyl, p-nitrobenzyloxycarbonyl, 

3,4-dimethoxy-6-nitrobenzyloxycarbonyl, 
2,4-dichloro-benzyloxycarbonyl, 5-benzylisoxazolylmethoxycarbonyl, 

9-anthranylmethoxy-carbonyl, 
diphenylmethoxycarbonyl, isonicotinyloxycarbonyl and 

S-benzyloxycarbonyl. 
Compound of general formula IV 

 
and the addition salts thereof,wherein: 


R represents hydrogen, hydroxy or halogen; 
R
1
 represents hydrogen or an -alk-X group wherein 

alk represents a (C
1
-C
4
) alkylene and 
X represents hydrogen, hydroxy, cyano, 
trifluoromethyl or a -NR
2
R
3
 group wherein R
2
 and R
3
 
independently represent hydrogen, (C
1
-C
4
) alkyl or an 
amino-protecting group selected from (C
1
-C
5
)alkoxycarbonyl, 
(C
2
-C
4
)alkenyloxycarbonyl, cinnamyloxycarbonyl, 
benzyloxycarbonyl, p-nitrobenzyloxycarbonyl, 3,4-dimethoxy-6-nitrobenzyloxy-carbonyl, 

2,4-dichlorobenzyloxycarbonyl, 
5-benzylisoxazolylmethoxycarbonyl, 

9-anthranylmethoxy-carbonyl, diphenylmethoxycarbonyl, 
isonicotinyloxycarbonyl and S-benzyloxycarbonyl; 
Y represents a group selected from (C
1
-C
5
)alkylmercapto, 
phenylmercapto, mono- or di- substituted phenyl 

mercapto wherein the substituents are selected from (C
1
-C
5
) 
alkyl and halogen, (C
1
-C
5
) alkylsulfinyl, phenylsulfinyl, 
mono- or di- substituted phenylsulfinyl wherein 

the substituents are selected from (C
1
-C
5
) alkyl and 
halogen, (C
1
-C
5
) alkylsulfonyl, phenylsulfonyl, mono- or 
di- substituted phenylsulfonyl wherein the substituents 

are selected from (C
1
-C
5
) alkyl and halogen, (C
1
-C
5
) 
alkylsulfonium hydrohalide salt, chloro and bromo. 
Compound of claim 1 wherein 

R is hydrogen or hydroxy; 
R
1
 is hydrogen or an -alk-X group wherein 

alk is a methylenic, ethylenic or propylenic 
moiety and 
X is hydrogen, hydroxy, cyano, trifluoromethyl, 
or a -NR
2
R
3
 group wherein R
2
 and R
3
 independently 
represent hydrogen, methyl, ethyl or 

butyloxycarbonyl. 
Compound of claims 1, 2 or 3 wherein the 
pharmaceutically acceptable salts thereof are formed 

with branched or linear mono-, di- or tri-alkylamines 
wherein the alkyl chain has 2 to 5 carbon atoms and 

contains at least one hydrophilic substituent selected 
from OH, SH and NH
2
 and whose pK value is comprised 
between 8 and 9.5 and basic natural and synthetic amino 

acids, in either L, D or racemic form, having a pK
3
 
value between 10 and 11; or, when the substituent X 

represents a -NR
2
R
3
 group, the pharmaceutically 
acceptable salts thereof are formed with hydrochloric, 

hydrobromic, sulfuric, phosphoric, acetic, 
trifluoroacetic, trichloroacetic, succinic, citric, 

ascorbic, lactic, maleic, fumaric, palmitic, cholic, 
pamoic, mucic, glutamic, camphoric, glutaric, glycolic, 

phthalic, tartaric, lauric, stearic, salicylic, 
methanesulfonic, benzenesulfonic, sorbic, picric, 

benzoic or cinnamic acid.  
 
Process for preparing a compound of claim 1 which 
comprises: 


a) On a compound of general formula II, 

 
wherein R represents hydrogen, hydroxy or halogen, when 

R represents an hydroxy group, protecting this hydroxy 
group, which is linked to the spiroketal moiety, by 

reacting it with a compound able to form a substituted 
(C
1
-C
3
)alkyl ether or an heterocyclic ether; 
b) protecting the remaining hydroxy groups linked 
to the aromatic moiety of said compound of general 

formula II, by reacting it with a compound able to form 
a (C
1
-C
3
) alkyl or aryl ester or a carbonate with such 
hydroxy group; 
c) submitting the obtained compound to an 
electrophylic substitution in position 6' by reacting it 

with a reactant able to insert in position 6' a moiety 
selected from (C
1
-C
5
) alkylmercapto, phenylmercapto, 
mono- or di- substituted phenyl mercapto wherein the 

substituents are selected from (C
1
-C
5
) alkyl and 
halogen, (C
1
-C
5
) alkylsulfinyl, phenylsulfinyl, mono- or 
di- substituted phenylsulfinyl wherein the substituents 

are selected from (C
1
-C
5
) alkyl and halogen, (C
1
-C
5
)  
 

alkylsulfonyl, phenylsulfonyl, mono- or di- substituted 
phenylsulfonyl wherein the substituents are selected 

from (C
1
-C
5
) alkyl and halogen, (C
1
-C
5
) alkylsulfonium 
hydrohalide salt, chloro and bromo; 
d) when R in the obtained compound represents a 
protected hydroxy function, selectively removing the 

protective group, by means of an hydrolytic cleavage; 
e) reacting the obtained compound in the presence of an organic aprotic solvent with a 
monosubstituted amine of general formula III 


NH
2
-alk-X
 
   wherein 


alk represents a (C
1
-C
4
) alkylene and 
X represents hydrogen, hydroxy, cyano, 
trifluoromethyl or a -NR
2
R
3
 group wherein R
2
 and R
3
 
independently represent hydrogen, (C
1
-C
4
) alkyl or an 
amino-protecting group selected from 

(C
1
-C
5
)alkoxycarbonyl, (C
2
-C
4
)alkenyloxycarbonyl, 
cinnamyloxycarbonyl, benzyloxycarbonyl, p-nitrobenzyloxycarbonyl, 

3,4-dimethoxy-6-nitrobenzyloxycarbonyl, 
2,4-dichloro-benzyloxycarbonyl, 

5-benzylisoxazolyl-methoxycarbonyl, 9-anthranylmethoxycarbonyl, 
diphenylmethoxycarbonyl, 

isonicotinyloxycarbonyl and S-benzyloxycarbonyl; 
f) Submitting the obtained amino-derivative to a 
selective hydrogenation in order to replace the 

substituent group in position 6' and, when R represents 
halogen, the halogen in position 4 with an hydrogen atom, in the presence of 

an hydrogenation catalyst and of a water miscible 
aprotic organic solvent. 
Process for preparing a compound of claim 1, which 
comprises: 


a) On a compound of general formula II 

 
when R represents an hydroxy group, protecting this 

hydroxy group, which is linked to the spiroketal moiety, 
by reacting it with a compound able to form a 

substituted (C
1
-C
3
)alkyl ether or an heterocyclic ether; 
b) protecting the remaining hydroxy groups linked 
to the aromatic moiety of said compound of general 

formula II, by reacting it with a compound able to form 
a (C
1
-C
3
) alkyl or aryl ester or a carbonate with such 
hydroxy group; 
c) submitting the obtained compound to an 
electrophylic substitution in position 6' by reacting it 

with a reactant able to insert in position 6' a moiety 
selected from (C
1
-C
5
) alkylmercapto, phenylmercapto, 
mono- or di- substituted phenyl mercapto wherein the 

substituents are selected from (C
1
-C
5
) alkyl and 
halogen, (C
1
-C
5
) alkylsulfinyl, phenylsulfinyl, mono- or 
di- substituted phenylsulfinyl wherein the substituents 

are selected from (C
1
-C
5
) alkyl and halogen, (C
1
-C
5
) 
alkylsulfonyl, phenylsulfonyl, mono- or di- substituted 

phenylsulfonyl wherein the substituents are selected  
 

from (C
1
-C
5
) alkyl and halogen, (C
1
-C
5
) alkylsulfonium 
hydrohalide salt, chloro and bromo; 
d) reacting the obtained compound in the presence of an organic aprotic solvent with a 
monosubstituted amine of general formula III 


NH
2
-alk-X
 
   wherein 


alk represents a (C
1
-C
4
) alkylene and 
X represents hydrogen, hydroxy, cyano, 
trifluoromethyl or a -NR
2
R
3
 group wherein R
2
 and R
3
 
independently represent hydrogen, (C
1
-C
4
) alkyl or an 
amino-protecting group selected from 

(C
1
-C
5
)alkoxycarbonyl, (C
2
-C
4
)alkenyloxycarbonyl, 
cinnamyloxycarbonyl, benzyloxycarbonyl, p-nitrobenzyloxycarbonyl, 

3,4-dimethoxy-6-nitrobenzyloxycarbonyl, 
2,4-dichloro-benzyloxycarbonyl, 

5-benzylisoxazolyl-methoxycarbonyl, 9-anthranylmethoxycarbonyl, 
diphenylmethoxycarbonyl, 

isonicotinyloxycarbonyl and S-benzyloxycarbonyl; 
e) when R in the obtained compound represents a 
protected hydroxy function, selectively removing the 

protective group, by means of an hydrolytic cleavage; 
f) Submitting the obtained amino-derivative to a 
selective hydrogenation in order to replace the 

substituent group in position 6' and, when R represents 
halogen, the halogen in position 4 with an hydrogen atom, in the presence of 

an hydrogenation catalyst and of a water miscible 
aprotic organic solvent. 
Process according to claim 5 or 6 wherein the 

protecting group of the hydroxy linked to the spiroketal 
is selected from methylthiomethyl ether, 

2-methoxyethoxymethyl ether, 2,2,2-trichloroethoxymethyl 
ether, bis(2-chloroethoxy)-methyl ether, 1-ethoxyethylether, 

1-isopropoxyethylether, tetrahydropyranyl ether, 3-bromotetrahydropyranyl  
 

ether, tetrahydrothiopyranyl ether, 
4-methoxy-tetrahydropyranyl ether, 4-methoxytetrahydrothiopyranyl 

ether, tetrahydrofuranyl ether or 
tetrahydrothiofuranyl ether. 
Process according to claim 5 or 6 wherein a 
weakly basic compound selected from a sodium, potassium, 

silver or ammonium (C
1
-C
3
)acylate, ammonium hydroxide, mono-, di- 
or tri- (C
1
-C
3
)alkylamines is added to the hydrogenating 
mixture of step f. 
Process according to claim 5, 6 or 8 wherein a 
water miscible polar organic solvent selected from 

(C
1
-C
4
)alcohols and glycols is added to the 
hydrogenating mixture of step f. 
Compound of general formula V 

 
wherein Hal is a chlorine or bromine atom. 
Process for preparing a compound of claim 10 by 
reacting purpuromycin with a chlorinating or brominating 

agent in order to insert in position 4 a chlorine or 
bromine atom. 
Process for preparing a compound of claim 1, 
wherein R represents hydrogen, which comprises: 


a) reacting a compound of general formula IV,  
 


 
wherein R
1
 has the meanings set forth in claim 1, R is 
hydroxy and Y represents (C
1
-C
5
) alkylmercapto, 
phenylmercapto, mono- or di- substituted phenyl mercapto 

wherein the substituents are selected from (C
1
-C
5
) alkyl 
and halogen, (C
1
-C
5
) alkylsulfinyl, phenylsulfinyl, 
mono- or di- substituted phenylsulfinyl wherein the 

substituents are selected from (C
1
-C
5
) alkyl and 
halogen, (C
1
-C
5
) alkylsulfonyl, phenylsulfonyl, mono- or 
di- substituted phenylsulfonyl wherein the substituents 

are selected from (C
1
-C
5
) alkyl and halogen, (C
1
-C
5
) 
alkylsulfonium hydrohalide salt, Cl or Br, with a 

chlorinating or brominating agent in order to insert in 
position 4 a chlorine or bromine atom; 
b) submitting the amino-derivative to a selective 
hydrogenation in order to replace the substituent group 

in position 6' and the halogen in position 4 with an hydrogen atom, in the 
presence of an hydrogenation catalyst and of a water 

miscible polar organic solvent. 
Process according to claim 11 or 12 wherein the 
chlorinating or brominating agent is triphenyl phosphine 

(PhP
3
) in CCl
4,
 polymer supported PhP
3
 in CCl
4
, PhP
3
·Cl
2
, 
PCl
3
 and ZnCl
2
 in dimethylformamide, AsCl
3
, PBr
3
, 
(CH
3
)
2
S·Br
2
 or SOCl
2
. 
Process for preparing a compound of claim 1, wherein 
R is hydrogen, by reacting a compound of claim 1,
  
 

wherein R is hydroxy, with an hydrogenating mixture able 
to remove the hydroxy group in position 4. 
Process according to claim 14 wherein the 
hydrogenating mixture is NaBH
3
CN and ZnI
2
 in 
dichloroethane, LiAlH
4
 and (Cyclopentadienil)
2
TiCl
2
 in THF 
or P
2
I
4
 in benzene. 
Process for preparing a compound of claim 1 
wherein R is hydrogen, comprising: 


a) reacting a compound of claim 1, wherein R 
represents hydroxy, in order to insert a mesylate, 

tosylate or xantate group in position 4; 
b) removing the mesylate, tosylate or xantate 
group by means of a selective hydrogenation 

reaction. 
Process according to claim 16 wherein the removal 
of the mesylate, tosylate or xantate group is performed 

with tri-butyltin hydride and sodium iodide in 
1,2-dimethoxyethane, Raney-Ni in dioxane-(C
1
-C
4
)alcohol, 
or But
3
SnH and Et
3
B in hexane, respectively. 
Compound according to claim 1 for use as 
medicament. 
Pharmaceutical composition containing as an active 
ingredient a compound of claim 1 in admixture with a 

pharmaceutically acceptable carrier. 
Use of a compound of claim 1 for preparing a 
medicament for treating vaginal infections. 
</CLAIMS>
</TEXT>
</DOC>
